A Phase 1 Study of VK3019 in Overweight and Obese Adults Without Comorbidities

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a Phase 1, randomized, double-blind, placebo-controlled single ascending dose (SAD) study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of VK3019 in overweight and obese adults without comorbidities.
Epistemonikos ID: e0590655da7efd5e4d6a9174e71b31ce8dcd5906
First added on: Sep 30, 2026